Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma

被引:0
作者
Matthew J. Ahearne
Kaljit Bhuller
Roger Hew
Hazem Ibrahim
Kikkeri Naresh
Simon D. Wagner
机构
[1] University of Leicester,Department of Cancer Studies and Molecular Medicine, Ernest and Helen Scott Haematology Research Institute and MRC Toxicology Unit
[2] Leicester Royal Infirmary,Department of Haematology
[3] Leicester Royal Infirmary,Department of Histopathology
[4] Imperial College Healthcare NHS Trust,Department of Histopathology
[5] University of Leicester,MRC Toxicology Unit
来源
Virchows Archiv | 2014年 / 465卷
关键词
Tfh; Treg; Diffuse large B-cell lymphoma;
D O I
暂无
中图分类号
学科分类号
摘要
The role of the microenvironment in high-grade lymphoma is not well defined. In this report, we employ immunohistochemistry to characterise programmed death-1 (PD-1/CD279) and FoxP3 expression in 70 cases of diffuse large B-cell lymphoma (DLBCL). PD-1 is a surface marker characteristic of follicular helper T-cells whilst FoxP3 is characteristic of Tregs. We demonstrate variable infiltration with CD4+ T-cells (<10 to >50 % of all lymph node cells) and PD-1hi cells (0.1 to 1.5 % of all cells). CD4+ T-cells can be distributed in clusters or more diffusely and PD-1hi cells, but not FoxP3+ cells, are found in rosettes around lymphoma cells. Cases with high CD4+ T-cell numbers tended to have higher numbers of both PD-1hi and FoxP3+ cells. Cases with total CD4+ T-cell, PD-1hi and FoxP3+ numbers above the median associate with better clinical outcome. Overall, we demonstrate that infiltration by CD4+ T-cells, including both FoxP3+ and PD-1hi subsets, correlates with prognosis in DLBCL. In distinction to previous reported series, patients (91 %) were treated with rituximab-containing regimens, suggesting that the effects of CD4+ T-cell infiltration are maintained in the rituximab era. This work suggests that determinants of total CD4+ T-cell infiltration, either molecular characteristics of the lymphoma or the patients’ immune system, and not individual T-cell subsets, correlate with clinical outcome.
引用
收藏
页码:351 / 358
页数:7
相关论文
共 116 条
[21]  
Ramiscal RR(2001)CD4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome J Clin Oncol 19 720-726
[22]  
Vinuesa CG(1990)Tumor-infiltrating T-lymphocytes in B-cell diffuse large cell lymphoma related to disease course Mod Pathol 3 361-367
[23]  
Shao H(2011)Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection Nat Immunol 12 663-671
[24]  
Chung J(2011)Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells Immunity 35 400-412
[25]  
Balaj L(2011)B cell priming for extrafollicular antibody responses requires Bcl-6 expression by T cells J Exp Med 208 1377-1388
[26]  
Mosmann TR(2009)Follicular helper T cells as cognate regulators of B cell immunity Curr Opin Immunol 21 266-273
[27]  
Coffman RL(2006)Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma Am J Surg Pathol 30 802-810
[28]  
Schmitt N(2011)Phenotype, effector function, and tissue localization of PD-1-expressing human follicular helper T cell subsets BMC Immunol 12 53-370
[29]  
Morita R(2012)Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring Diagn Pathol 7 42-2290
[30]  
Bourdery L(2013)Enhancement of CD154/IL4 proliferation by the T follicular helper (Tfh) cytokine, IL21 and increased numbers of circulating cells resembling Tfh cells in chronic lymphocytic leukaemia Br J Haematol 162 360-2964